biostudies-literatureUnknown16Lwin SMCytokine-targeted biologics have revolutionized the management of moderate-to-severe psoriasis; however, all available therapies have failed a growing number of patients. Mesenchymal stromal cells (MSCs), with their immunomodulatory properties, offer a novel therapeutic option. Here, we report the cases of three adult female patients with long-standing, severe plaque psoriasis who were refractory to multiple biologic therapies, and were consequently treated with two intravenous infusions of allogeneic umbilical cord-derived MSCs (UC-MSCs; 1.96 - 3.00 × 10⁶ cells/kg) 1 week (W) apart. Two patients received UC-MSCs as monotherapy; one received them alongside etanercept. Upon relapse, two patients resumed their last failed biologic at W9, while one switched to a new biologic at W24Frontiers in immunology1656724https://www.ebi.ac.uk/biostudies/studies/S-EPMC12440939biostudies-literatureMesenchymal stromal cells as rescue therapy in biologic-refractory psoriasis: insights from a case series.PMC12440939Walsh SMcGrath JASolanky SAl-Haddabi AScotta CDawe HDazzi FLombardi GDi Meglio PLwin SMGriffiths CEMAzrielant SDuarte-Williamson ETosi IGiacomini CfalseMesenchymal stromal cells as rescue therapy in biologic-refractory psoriasis: insights from a case series.Cytokine-targeted biologics have revolutionized the management of moderate-to-severe psoriasis; however, all available therapies have failed a growing number of patients. Mesenchymal stromal cells (MSCs), with their immunomodulatory properties, offer a novel therapeutic option. Here, we report the cases of three adult female patients with long-standing, severe plaque psoriasis who were refractory to multiple biologic therapies, and were consequently treated with two intravenous infusions of allogeneic umbilical cord-derived MSCs (UC-MSCs; 1.96 - 3.00 × 10⁶ cells/kg) 1 week (W) apart. Two patients received UC-MSCs as monotherapy; one received them alongside etanercept. Upon relapse, two patients resumed their last failed biologic at W9, while one switched to a new biologic at W242025-01-01T00:00:00Z20252026-06-03T12:06:41.967Z2026-04-27T03:11:30.88ZS-EPMC124409394096975710.3389/fimmu.2025.1656724